Comparison Guide,TIDES is the industry's premier event series

The AsiaTIDES: Oligonucleotide & Peptide Therapeutics 2018 conference served as a pivotal gathering for leaders and innovators in the field of oligonucleotide and peptide-based medicines. This exclusive event, held in the Asia-Pacific region, brought together a diverse group of experts, including scientists, researchers, and industry professionals, all focused on accelerating the development and commercialization of these cutting-edge therapeutic modalities. The conference highlighted the growing significance of oligonucleotides and peptides as two of the fastest-growing and most promising modalities within the pharmaceuticals sector.

At the heart of AsiaTIDES: Oligonucleotide & Peptide Therapeutics 2018, discussions revolved around key advancements and challenges in the development of oligonucleotide therapeutics and peptide drugs. The event provided a platform for sharing advanced CMC strategies for oligonucleotide and peptide drugs, crucial for ensuring the quality, safety, and efficacy of these complex molecules. Presentations and discussions delved into the latest scientific discoveries, technological innovations, and regulatory landscapes shaping the future of this rapidly evolving field.

The significance of AsiaTIDES as a premier event in Asia for exchanging strategies and best practices was evident throughout the proceedings. Experts in oligonucleotides, peptides, mRNA, and genome editing converged to explore new frontiers in drug discovery and development. The conference also touched upon the potential of oligonucleotide- and protein/peptide-based therapeutics in managing various diseases, underscoring the broad applicability and therapeutic promise of these molecular classes.

A notable aspect of AsiaTIDES: Oligonucleotide & Peptide Therapeutics 2018 was the emphasis on bridging the gap between research and market. The event fostered collaborations and partnerships, aiming to accelerate the journey of oligonucleotide and peptide molecules from the laboratory bench to commercial success. This aligns with the broader industry trend where TIDES is the industry's premier event series focused on this objective.

Furthermore, the conference provided insights into the manufacturing and scale-up processes. Discussions on topics such as Fitusiran and donidalorsen are the first oligonucleotide therapies approved for specific genetic disorders, exemplified the tangible progress being made. The introduction of novel solutions, such as Haelium Oligonucleotide and Peptide Reagents, aimed at optimizing synthesis processes, also contributed to the discourse on efficient and scalable manufacturing.

The AsiaTIDES: Oligonucleotide & Peptide Therapeutics 2018 event served as a crucial stepping stone, building upon the momentum of previous years and setting the stage for future advancements. The insights shared and connections forged during this conference continue to drive innovation in the development of life-changing oligonucleotide and peptide therapies. The focus on PepTIDE Drug discovery and development, alongside other nucleic acid-based therapeutics, reinforces the multidisciplinary approach required to tackle complex health challenges. The continuous evolution of TIDES Asia into subsequent years, with events like TIDES Asia 2025 and TIDES Asia 2026, demonstrates the sustained and growing importance of this field.